Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | rAD-p53 |
Synonyms | |
Therapy Description |
Gendicine (rAD-p53) is a replication-defective adenoviral vector encoding wild-type TP53, which induces tumor cells to produce wild-type Tp53 and potentially induce apoptosis. Gendicine may also stimulate a cytotoxic T-lymphocyte immune response against tumor cells, and activate natural killer cells (PMID: 29338444, PMID: 32013587, PMID: 30618300). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
rAD-p53 | Gendicine|Genkaxin | p53 Gene Therapy 4 | Gendicine (rAD-p53) is a replication-defective adenoviral vector encoding wild-type TP53, which induces tumor cells to produce wild-type Tp53 and potentially induce apoptosis. Gendicine may also stimulate a cytotoxic T-lymphocyte immune response against tumor cells, and activate natural killer cells (PMID: 29338444, PMID: 32013587, PMID: 30618300). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01574729 | Phase II | rAD-p53 | Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma | Unknown status | 1 |